LT2616076T - Farmacinės kompozicijos - Google Patents

Farmacinės kompozicijos

Info

Publication number: LT2616076T
Authority: LT; Lithuania
Prior art keywords: pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 2010-09-16

Application number

LTEP11825920.9T

Other languages

English (en)

Inventor

Deepak B. Mundhra

Rennan Pan

Original Assignee

Viiv Healthcare Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-16

Filing date

2011-09-15

Publication date

2016-10-10

2011-09-15 Application filed by Viiv Healthcare Company filed Critical Viiv Healthcare Company

2016-10-10 Publication of LT2616076T publication Critical patent/LT2616076T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

LTEP11825920.9T 2010-09-16 2011-09-15 Farmacinės kompozicijos LT2616076T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38354110P	2010-09-16	2010-09-16
PCT/US2011/051713 WO2012037320A2 (en)	2010-09-16	2011-09-15	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
LT2616076T true LT2616076T (lt)	2016-10-10

Family

ID=45832235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP11825920.9T LT2616076T (lt)	2010-09-16	2011-09-15	Farmacinės kompozicijos

Country Status (28)

Country	Link
US (7)	US20130171214A1 (lt)
EP (1)	EP2616076B1 (lt)
JP (1)	JP6231385B2 (lt)
KR (1)	KR101938662B1 (lt)
CN (1)	CN103547266B (lt)
AU (1)	AU2011302030B2 (lt)
BR (1)	BR112013005907B1 (lt)
CA (1)	CA2810524C (lt)
CL (1)	CL2013000715A1 (lt)
CY (1)	CY1118279T1 (lt)
DK (1)	DK2616076T3 (lt)
EA (1)	EA024924B1 (lt)
ES (1)	ES2594557T3 (lt)
HR (1)	HRP20161280T1 (lt)
HU (1)	HUE031336T2 (lt)
IL (1)	IL225028A (lt)
LT (1)	LT2616076T (lt)
ME (1)	ME02520B (lt)
MX (1)	MX346193B (lt)
PL (1)	PL2616076T3 (lt)
PT (1)	PT2616076T (lt)
RS (1)	RS55222B1 (lt)
SI (1)	SI2616076T1 (lt)
SM (1)	SMT201600350B (lt)
TW (1)	TWI577377B (lt)
UA (1)	UA108250C2 (lt)
WO (1)	WO2012037320A2 (lt)
ZA (1)	ZA201301766B (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3387B1 (ar)	2011-12-16	2019-03-13	Glaxosmithkline Llc	مشتقات بيتولين
SG10201704467SA (en) *	2012-12-14	2017-06-29	Glaxosmithkline Llc	Pharmaceutical compositions
WO2015108945A2 (en)	2014-01-14	2015-07-23	Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
WO2015127437A1 (en) *	2014-02-24	2015-08-27	The Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
MX2017003928A (es) *	2014-09-26	2017-06-28	Glaxosmithkline Intellectual Property (No 2) Ltd	Composiciones farmaceuticas de accion prolongada.
EP3203995A4 (en)	2014-10-09	2019-05-15	Board of Regents of the University of Nebraska	COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
CA2969303A1 (en) *	2014-12-20	2016-06-23	Troikaa Pharmaceuticals Limited	Injectable formulations of paracetamol
JP7160466B2 (ja) *	2016-06-23	2022-10-25	ヴィーブヘルスケアカンパニー	治療薬の送達のための組成物及び方法
US11077050B2 (en)	2017-03-24	2021-08-03	Merck Sharp & Dohme Corp.	Formulation for parenteral administration
CA3069069A1 (en)	2017-07-14	2019-01-17	Janssen Pharmaceutica Nv	Long-acting formulations
JP2020527570A (ja) *	2017-07-18	2020-09-10	ヴィーブヘルスケアカンパニー	組み合わせ薬物療法
EP3737359A4 (en)	2018-01-12	2021-11-03	Board of Regents of the University of Nebraska	ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
WO2019199756A1 (en)	2018-04-09	2019-10-17	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and formulations thereof
WO2020086555A1 (en)	2018-10-22	2020-04-30	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and nanoformulations thereof
US20220175936A1 (en)	2018-11-29	2022-06-09	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and nanoformulations thereof
CN109646440B (zh) *	2019-01-11	2021-04-20	山东省农业科学院奶牛研究中心	Cabotegravir在制备抗牛传染性鼻气管炎药物中的应用
CA3128961A1 (en)	2019-03-22	2020-10-01	Hang CHU	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
AU2020402659A1 (en) *	2019-12-09	2022-06-02	Viiv Healthcare Company	Pharmaceutical compositions comprising cabotegravir
IL295677A (en)	2020-02-24	2022-10-01	Gilead Sciences Inc	Tetracyclic compounds for treating hiv infection
JP2023533014A (ja) *	2020-07-09	2023-08-01	ヤンセンファーマシューティカエヌ．ベー．	長時間作用型配合物
WO2022008644A1 (en) *	2020-07-09	2022-01-13	Janssen Pharmaceutica Nv	Long-acting formulations
US20230321089A1 (en) *	2020-09-01	2023-10-12	Viiv Healthcare Company	Combination of cabotegravir and levonorgestrel
EP4222152A1 (en)	2020-09-30	2023-08-09	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine
TW202408533A (zh)	2021-01-19	2024-03-01	美商基利科學股份有限公司	經取代之吡啶并三𠯤化合物及其用途
TWI856796B (zh)	2022-04-06	2024-09-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
CN115844838B (zh) *	2022-12-01	2023-10-24	浙江萃泽医药科技有限公司	一种可注射的药物组合物
WO2025181723A1 (en)	2024-03-01	2025-09-04	ViiV Healthcare UK (No.3) Limited	Dosing regimen
CN120424092B (zh) *	2025-07-02	2025-09-12	中国人民解放军军事科学院军事医学研究院	布尼亚病毒抑制剂及其制备方法和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1215599A (fr) *	1958-06-27	1960-04-19	Rhone Poulenc Sa	Nouveaux dérivés de l'iminodibenzyle substitués à l'azote par une chaîne pipérazinique et leur préparation
US5352459A (en)	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5484926A (en)	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
KR100571215B1 (ko)	1995-06-07	2006-10-24	트라이머리스 인코퍼레이티드	복합적인치료요법을이용한hiv와다른바이러스감염의치료
US5834025A (en) *	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
TW487572B (en)	1996-05-20	2002-05-21	Janssen Pharmaceutica Nv	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6045829A (en)	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6066292A (en) *	1997-12-19	2000-05-23	Bayer Corporation	Sterilization process for pharmaceutical suspensions
TW518218B (en) *	1999-05-27	2003-01-21	Merck Patent Gmbh	Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
JP5160005B2 (ja) *	2000-12-28	2013-03-13	武田薬品工業株式会社	徐放性製剤
CA2491466A1 (en) *	2002-07-09	2004-01-15	Sharlene Adams	Methods and compositions relating to isoleucine boroproline compounds
AU2003265511A1 (en) *	2002-08-21	2004-03-11	Pharmacia Corporation	Injectable pharmaceutical suspension in a two-chamber vial
JP2007501683A (ja)	2003-05-22	2007-02-01	エランファーマインターナショナルリミテッド	γ線照射によるナノ粒子活性物質分散体の滅菌法
EP1713443A2 (en)	2004-01-29	2006-10-25	Baxter International Inc.	Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
US7985222B2 (en)	2004-04-21	2011-07-26	Medshape Solutions, Inc.	Osteosynthetic implants and methods of use and manufacture
CN101163702B (zh)	2005-04-25	2011-09-07	詹森药业有限公司	制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
EP3284519A1 (en) *	2005-04-28	2018-02-21	VIIV Healthcare Company	Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2007053189A2 (en) *	2005-06-01	2007-05-10	Northwestern University	Compositions and methods for altering immune function
CA2611592A1 (en)	2005-06-17	2006-12-21	Hospira Australia Pty Ltd	Liquid pharmaceutical formulations of docetaxel
US20070001094A1 (en)	2005-06-29	2007-01-04	Micron Technology, Inc.	Infrared filter for imagers
EA014914B1 (ru) *	2006-01-20	2011-02-28	Тиботек Фармасьютикалз Лтд.	Долговременное лечение вич-инфекции
US20070178051A1 (en)	2006-01-27	2007-08-02	Elan Pharma International, Ltd.	Sterilized nanoparticulate glucocorticosteroid formulations
MX2009000158A (es)	2006-06-23	2009-01-23	Tibotec Pharm Ltd	Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil ]-amino]-2-pirimidinil]-amino]-benzonitrilo.
ES2437331T3 (es) *	2007-07-12	2014-01-10	Janssen R&D Ireland	Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
WO2009080651A1 (en) *	2007-12-19	2009-07-02	Janssen Pharmaceutica Nv	Dosing regimen associated with long acting injectable paliperidone esters
TWI532498B (zh)	2008-03-17	2016-05-11	巴克斯特保健公司	供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20090311237A1 (en) *	2008-04-14	2009-12-17	Frost Gregory I	Combination therapy using a soluble hyaluronidase and a bisphosphonate
US8648119B2 (en) *	2008-05-23	2014-02-11	Otonomy, Inc.	Controlled release immunomodulator compositions and methods for the treatment of otic disorders
KR101772610B1 (ko) *	2008-07-25	2017-09-12	비이브 헬쓰케어 컴퍼니	화합물
WO2010011815A1 (en) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
CN104788367A (zh)	2008-12-11	2015-07-22	盐野义制药株式会社	氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
ES2641765T3 (es)	2008-12-11	2017-11-13	Shionogi & Co., Ltd.	Síntesis de inhibidores de integrasa de VIH carbamoilpiridona y productos intermedios
WO2011017395A1 (en)	2009-08-04	2011-02-10	Glaxosmithkline Llc	Chemical compounds
US20110152303A1 (en)	2009-12-18	2011-06-23	Glaxosmithkline Llc	Chemical Compounds

2011
- 2011-09-14 TW TW100133064A patent/TWI577377B/zh active
- 2011-09-15 HU HUE11825920A patent/HUE031336T2/hu unknown
- 2011-09-15 RS RS20160826A patent/RS55222B1/sr unknown
- 2011-09-15 KR KR1020137009569A patent/KR101938662B1/ko active Active
- 2011-09-15 AU AU2011302030A patent/AU2011302030B2/en active Active
- 2011-09-15 MX MX2013003037A patent/MX346193B/es active IP Right Grant
- 2011-09-15 EA EA201390233A patent/EA024924B1/ru unknown
- 2011-09-15 SI SI201130966A patent/SI2616076T1/sl unknown
- 2011-09-15 CN CN201180044588.5A patent/CN103547266B/zh active Active
- 2011-09-15 PT PT118259209T patent/PT2616076T/pt unknown
- 2011-09-15 ME MEP-2016-192A patent/ME02520B/me unknown
- 2011-09-15 HR HRP20161280TT patent/HRP20161280T1/hr unknown
- 2011-09-15 BR BR112013005907-9A patent/BR112013005907B1/pt active IP Right Grant
- 2011-09-15 LT LTEP11825920.9T patent/LT2616076T/lt unknown
- 2011-09-15 US US13/823,316 patent/US20130171214A1/en not_active Abandoned
- 2011-09-15 JP JP2013529316A patent/JP6231385B2/ja active Active
- 2011-09-15 WO PCT/US2011/051713 patent/WO2012037320A2/en active Application Filing
- 2011-09-15 CA CA2810524A patent/CA2810524C/en active Active
- 2011-09-15 UA UAA201303057A patent/UA108250C2/ru unknown
- 2011-09-15 ES ES11825920.9T patent/ES2594557T3/es active Active
- 2011-09-15 IL IL225028A patent/IL225028A/en active IP Right Grant
- 2011-09-15 DK DK11825920.9T patent/DK2616076T3/en active
- 2011-09-15 PL PL11825920T patent/PL2616076T3/pl unknown
- 2011-09-15 EP EP11825920.9A patent/EP2616076B1/en active Active
2013
- 2013-03-07 ZA ZA2013/01766A patent/ZA201301766B/en unknown
- 2013-03-15 CL CL2013000715A patent/CL2013000715A1/es unknown
2016
- 2016-10-04 SM SM201600350T patent/SMT201600350B/it unknown
- 2016-10-04 CY CY20161100985T patent/CY1118279T1/el unknown
- 2016-10-13 US US15/292,394 patent/US11224597B2/en active Active
2021
- 2021-12-10 US US17/547,682 patent/US20220096469A1/en not_active Abandoned
2024
- 2024-05-31 US US18/679,621 patent/US12138264B2/en active Active
- 2024-10-01 US US18/903,119 patent/US20250017923A1/en not_active Abandoned
- 2024-10-01 US US18/903,140 patent/US20250017924A1/en not_active Abandoned
2025
- 2025-05-15 US US19/208,707 patent/US20250268893A1/en active Pending

Also Published As

Publication number	Publication date
US11224597B2 (en)	2022-01-18
CL2013000715A1 (es)	2013-07-05
TW201223529A (en)	2012-06-16
PT2616076T (pt)	2016-09-30
US20250017924A1 (en)	2025-01-16
RS55222B1 (sr)	2017-02-28
MX346193B (es)	2017-03-10
US20250268893A1 (en)	2025-08-28
AU2011302030A1 (en)	2013-04-04
CY1118279T1 (el)	2017-06-28
CN103547266A (zh)	2014-01-29
CA2810524C (en)	2018-06-26
HRP20161280T1 (hr)	2016-11-18
US20250017923A1 (en)	2025-01-16
SMT201600350B (it)	2016-11-10
ES2594557T3 (es)	2016-12-21
ZA201301766B (en)	2016-11-30
US20130171214A1 (en)	2013-07-04
US20170027933A1 (en)	2017-02-02
BR112013005907A2 (pt)	2016-06-07
JP2014500849A (ja)	2014-01-16
JP6231385B2 (ja)	2017-11-15
US20220096469A1 (en)	2022-03-31
KR101938662B1 (ko)	2019-01-15
BR112013005907B1 (pt)	2021-04-27
PL2616076T3 (pl)	2017-07-31
IL225028A (en)	2017-04-30
EA201390233A1 (ru)	2014-03-31
UA108250C2 (uk)	2015-04-10
HUE031336T2 (hu)	2017-07-28
EP2616076B1 (en)	2016-07-13
MX2013003037A (es)	2013-09-02
CN103547266B (zh)	2016-04-06
US12138264B2 (en)	2024-11-12
EP2616076A2 (en)	2013-07-24
EA024924B1 (ru)	2016-11-30
WO2012037320A2 (en)	2012-03-22
DK2616076T3 (en)	2016-10-24
WO2012037320A3 (en)	2014-03-27
KR20130116254A (ko)	2013-10-23
CA2810524A1 (en)	2012-03-22
US20240307387A1 (en)	2024-09-19
EP2616076A4 (en)	2015-01-21
AU2011302030B2 (en)	2015-01-22
SI2616076T1 (sl)	2016-11-30
ME02520B (me)	2017-02-20
TWI577377B (zh)	2017-04-11

Publication	Publication Date	Title
IL245326B (en)	2021-04-29	pharmaceutical preparation
ZA201300458B (en)	2013-09-25	C-met-modulator pharmaceutical compositions
ZA201301766B (en)	2016-11-30	Pharmaceutical compositions
IL223535A (en)	2017-02-28	Solid medicinal compositions
ZA201207670B (en)	2013-05-29	Pharmaceutical compositions
IL225457A0 (en)	2013-06-27	Pharmaceutical composition
LT2619182T (lt)	2017-01-25	Farmacinė kompozicija
ZA201300718B (en)	2013-08-28	Pharmaceutical compositions
PT2579858E (pt)	2014-07-18	Composição farmacêutica que contém ivabradina
ZA201301920B (en)	2013-10-30	Pharmaceutical composition
GB201010453D0 (en)	2010-08-04	Pharmaceutical composition
ZA201303223B (en)	2014-01-29	Pharmaceutical compositions
ZA201303177B (en)	2018-12-19	Pharmaceutical compositions
IL226554A (en)	2017-12-31	Medicinal preparations containing alisporiovir
IL221501A (en)	2016-11-30	Medicinal product containing miramistine
GB201001911D0 (en)	2010-03-24	Pharmaceutical composition
EP2560678A4 (en)	2013-09-18	PHARMACEUTICAL COMPOSITIONS
ZA201303732B (en)	2018-12-19	Pharmaceutical compositions
GB201008590D0 (en)	2010-07-07	Pharmaceutical compositions
GB201005403D0 (en)	2010-05-12	Novel pharmaceutical compositions
GB201019775D0 (en)	2011-01-05	Pharmaceutical composition
HU1000006D0 (en)	2010-03-01	Improved pharmaceutical composition